Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐ResistantStreptococcus pneumoniae
about
Macrolide Resistance in Streptococcus pneumoniaeClinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial.Increase in pneumococcus macrolide resistance, United States.Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzaeAntimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona.Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?Serotypes and patterns of antibiotic resistance in strains causing invasive pneumococcal disease in children less than 5 years of age.Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid.In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.Changing needs of community-acquired pneumonia.Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniaePrevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.Macrolide resistance in adults with bacteremic pneumococcal pneumonia.Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update.Hidden epidemic of macrolide-resistant pneumococci.Genotypes and serotype distribution of macrolide resistant invasive and non-invasive Streptococcus pneumoniae isolates from Lebanon.Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia.Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient.Blood cultures in ambulatory patients who are discharged from emergency with community-acquired pneumoniaAzithromycin and lower respiratory tract infections.Comparison of amoxicillin with alternative agents for the treatment of acute otitis media in children.Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics.The search for new antimicrobials: why we need new options.Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.Clinical implications of macrolide resistance in community-acquired respiratory tract infections.Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia.Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Ukraine.Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam.Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.Clinical applications of azithromycin microspheres in respiratory tract infections
P2860
Q28070243-9A5AF4FD-8808-4E39-8191-D123048C3893Q30830558-901BFA16-98D4-4B1F-9FBF-7B916B7BA2D4Q33584747-BF857AEA-22FD-4154-8FE1-FAA319007CCCQ33628610-6B6A54C3-2466-48AA-AD45-C9F66C25E90EQ33684318-68D5F15E-B72D-496F-9B18-D6F0613FBE65Q33739099-F7D54FD0-6C5C-4616-A50C-25B1FDA312F7Q33856741-EEA1090A-15FF-4BF7-8B2D-94DE93C392E3Q33938055-903F9FB8-C367-473C-8317-DEFD8F2E7360Q34129492-D4E9055D-4E34-4E70-9627-9463EA587726Q34375192-7A903DB2-7AFB-41C2-83FE-604E8FB7CFE8Q34559255-39F3A669-B8BB-42A7-95CA-D37BA89EEA4AQ34587708-30035CCD-B783-4B22-95C9-C49E882AC27FQ35006670-65E43896-BAE5-4E5A-BC3F-00941CBF9EE4Q35127530-7771C942-899B-4351-A221-BA2493CB55F5Q35547345-6DCACEC6-786E-45DF-A13A-E7CDE88BEF85Q35690406-5202772F-0DA5-427F-8E35-FCB9DBCFC52DQ35692693-FB8BC451-176D-480B-8436-A639C2729BA2Q35784460-66548D30-477A-4CE5-8C82-3923722549ADQ35793210-A7D35242-A287-4203-BC86-735E6A551381Q35880906-BD580E3C-E3F8-4CF2-8A9D-816735D18778Q35951616-0F4B9A1B-42BC-4803-82B7-F17604A49CB8Q36009405-AE1D71C0-6085-4550-9D13-3F4AA9ACB03BQ36022068-F28F264C-E130-410C-8791-B6E8C7035703Q36082717-634C525D-BC94-4158-9344-17D34B16003FQ36161246-22EBC61B-3C72-4F6C-9F2A-617D01C6CD3EQ36170729-4CFE5366-9859-4269-9A56-4F022A93415AQ36283753-095AB4F3-6BE8-4FAD-ABCD-006F27C67926Q36320599-24E4B757-C26D-487C-BD61-65994B29544BQ36320613-9B8C79DE-7F1E-45C3-9FE5-36AC3E247D1AQ36322113-523B140A-9ADE-4FDF-8C9E-E6C58F7806BCQ36342239-19DE64D6-EE3E-467A-B317-CBD6D2E1DFEBQ36487417-F75D8943-9FCC-4F03-9FC2-73C7FA735C8EQ36670675-1892F48A-935C-462E-AAE1-932000FF5BB4Q36670897-E7566406-DFE3-412E-A66C-7B580B8C10EEQ36688947-34E994F6-3E6C-47ED-909F-E42A7456955EQ36703015-E14EF8D5-3521-4FA5-A3E7-FF6D97DA6D70Q36960328-81930BC0-E3CE-4C3B-8853-2B32322925B1Q36960334-CE6C5C30-8906-43D7-AC73-3227B54DE40CQ37026706-60D16350-92D2-46F0-916B-29FFD42F767BQ37059889-34672088-191D-440E-A431-86265862FFD4
P2860
Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐ResistantStreptococcus pneumoniae
description
article
@en
im August 2002 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2002
@uk
name
Failure of Macrolide Antibioti ...... istantStreptococcus pneumoniae
@en
Failure of Macrolide Antibioti ...... istantStreptococcus pneumoniae
@nl
type
label
Failure of Macrolide Antibioti ...... istantStreptococcus pneumoniae
@en
Failure of Macrolide Antibioti ...... istantStreptococcus pneumoniae
@nl
prefLabel
Failure of Macrolide Antibioti ...... istantStreptococcus pneumoniae
@en
Failure of Macrolide Antibioti ...... istantStreptococcus pneumoniae
@nl
P2093
P2860
P356
P1476
Failure of macrolide antibioti ...... stant Streptococcus pneumoniae
@en
P2093
Anna Ochoa de Echagüen
Antone A Medeiros
Javier Garau
John R Lonks
Lucía Gomez
Mariona Xercavins
P2860
P304
P356
10.1086/341978
P407
P577
2002-08-09T00:00:00Z